CLSP 1025
Alternative Names: CLSP-1025Latest Information Update: 04 Jul 2025
At a glance
- Originator Clasp Therapeutics
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 28 Feb 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06778863)
- 17 Jan 2025 Clasp Therapeutics plans a phase I GUARDIAN-101 clinical trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) (IV Infusion) in January 2025 (NCT06778863)